- 
- 2 Title page
- 

4 Title: Changing species dynamics and species-specific associations observed between *Anopheles* and *Plasmodium* genera in Diebougou health district, southwest Burkina Faso 

- 7 Authors: Lado P<sup>1^</sup>, Gray LI<sup>1^</sup>, Sougué E<sup>4^</sup>, Knight AL<sup>1</sup>, Sorensen M<sup>1</sup>, Leon AS<sup>1</sup>, Ring ME<sup>1</sup>, Pugh
- $G<sup>1</sup>$ , Randall JC<sup>1</sup>, Coffin KL<sup>1</sup>, Hemming-Schroeder E<sup>1</sup>, Goodwin J<sup>2</sup>, Wade M<sup>2</sup>, Sproch H<sup>2</sup>,
- 9 Ouédraogo COW<sup>4</sup>, Dah SR<sup>4</sup>, Somé AF<sup>4</sup>, Dabiré RK<sup>4</sup>, Parikh S<sup>2</sup>, Foy BD<sup>1\*</sup>
- 

1Center for Vector-borne Infectious Diseases, Department of Microbiology, Immunology and

- 12 Pathology, Colorado State University, Fort Collins, CO, USA; <sup>2</sup>Department of Epidemiology of
- 13 Microbial Diseases, Yale School of Public Health, New Haven, CT, USA; <sup>3</sup>Center for Innovative
- Design and Analysis, University of Colorado Anschutz Medical Campus, Aurora, CO, USA;
- 15 <sup>4</sup> Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest, Bobo-
- Dioulasso, Burkina Faso; ^These authors contributed equally; \*Corresponding Author

### Abstract

- The prevalence of malaria parasite species in parts of Africa is rapidly changing and influenced
- by detection methods. The natural vector competence and vectorial capacity of African
- anophelines for human *Plasmodium* species has only been well described for *P. falciparum* and
- is unclear in the context of mixed and non-falciparum infections. Over the course of two clinical
- trials (2015 and 2019-2020) testing ivermectin for malaria control in the same region of Burkina
- Faso, we sampled participants' blood and their households for *Anopheles* spp. mosquitoes and
- tested these samples for *Plasmodium* species. *Plasmodium* prevalence in participants and their
- blood samples was high in both trials. While *P. falciparum* mono-infections comprised most
- 27 infections in the 1<sup>st</sup> trial, mixed and non-falciparum infections comprised 27% of infections in the
- 28 2<sup>nd</sup> trial, with notable changes in species present within participants over time. Furthermore, An. *gambiae* s.l. was the main vector captured, but *An. funestus* mosquitoes were unexpectedly
- 30 prevalent in the  $2<sup>nd</sup>$  trial, and we found that parasite species prevalence differed in abdominal
- and head+thorax tissues of these two vector species. Most notably, *P. falciparum* sporozoites
- were significantly more prevalent than other parasite species in *An. gambiae* s.l. while *P. ovale*
- sporozoites were significantly more prevalent than other parasite species in *An. funestus*. Our
- data suggest differential vector competence for *Plasmodium* species at the study site, which
- may significantly impact malaria epidemiology, disease prevalence and control efforts.
- 
- 
- 
- 
- 
- 
- 
- 

#### **Introduction**

 Malaria, caused by *Plasmodium* parasites transmitted by *Anopheles* mosquitoes, is one of the most prevalent infectious diseases in Africa and other parts of the tropics. Of the estimated 249 million cases worldwide, 48.5% occur in West Africa. Burkina Faso is among the most affected 50 countries, ranking  $6<sup>th</sup>$  in malaria cases and  $9<sup>th</sup>$  deaths globally (1). Efforts to control the disease burden in the country, similar to other high transmission countries in West Africa, includes using point-of-care (POC) rapid diagnostic tests (RDT) and treatment with artemisinin-based combined therapies (ACT), intermittent preventative treatment in pregnancy (IPTp), and use of seasonal malaria chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP) plus amodiaquine (AQ). To control transmission, health authorities perform community distributions of insecticide-treated bed nets (ITN) approximately every 2-4 years, which more recently includes distribution of nets containing more than one chemical (dual-chemistry nets), and less often conduct indoor residual spraying (IRS) of insecticides in specific regions (2, 3). Despite these efforts, the malaria burden in Burkina Faso has remained high with increasing incidence

- for nearly a decade (4, 5).
- 

Potential causes for the intransigence of malaria in Burkina Faso despite these intensive control

efforts are many. Socioeconomic factors such as high rates of poverty, limited community

uptake and/or compliance with parasite and vector control tools, political upheaval with high

migrant flows, and extensive artisanal gold mining across the country all likely contribute to the

- current situation (6-11). Within- and between-species parasite diversity is also underappreciated
- and represents an additional challenge of malaria control in high burden countries. Infections
- with a diversity of genotypic clones of *Plasmodium falciparum* (*Pf*) are common in such settings
- and correlated to higher malaria incidence among young children in many settings (12-14). In
- center-west Burkina Faso, higher diversity (multiplicity of infection; MOI) of *Pf* genotypes among

those presenting with malaria correlated with periods of higher malaria incidence, and overall

 MOI decreased with advancing age (15). In southwestern Burkina Faso, using amplicon deep sequencing, we recently demonstrated that asymptomatic individuals harbored a mean of 3.1

distinct *Pf* clones per sampling timepoint spanning across wet and dry seasons, each of which

could theoretically have different genetics relating to antimalarial drug resistance,

immunogenicity, or other factors relating to disease processes (16).

Parasite species diversity also complicates malaria control, but a recognition of the scope of

such diversity within different African regions is only recently emerging. Reports over the past

several years have demonstrated unexpected or increasing prevalence of *Plasmodium malariae* 

*(Pm)*, with its unique 72-hour life cycle, and *P. ovale (Po)* species *and P. vivax (Pv)* with their

dormant hypnozoite stages in certain regions (17-19). More limited data from West Africa

suggest unexpected prevalence or increases in non-falciparum species in parts of Burkina Faso

 and other countries (20-22). The lack of detection of non-falciparum species is not surprising because these species tend to maintain lower peripheral parasite densities and therefore are

less likely to be detected by microscopy and RDTs (23-25). In addition, African countries nearly

universally lack treatment policies which support anti-relapse treatment of dormant hypnozoites

of *Po* species and *Pv*, leaving a persistent and unaddressed reservoir within the continent (26).

#### 

 On the vector side, there is similarly high diversity both within and between mosquito species across Burkina Faso which varies from the dry Sahel ecozone in the north with a short but intense rainy season to the Sudanian ecozone in the south with a longer rainy season (27-37). *Anopheles gambiae* s.s. and *An. coluzzi* typically have the highest human biting rates in rural and semi-rural areas during the rainy seasons (38, 39), while *An. arabiensis* drives malaria transmission in urban centers especially during the dry seasons (32). In other landscapes, different species can be the primary vectors, including *An. funestus* group species around areas with more permanent water sources such as dams, swamps and ponds (39-42), and *An. nili* which breeds along the edges of rivers and streams in the south (43). Highly zoophagic and exophagic vectors such as *An. squamosis*, *An. rufipes*, *An. coustani*, and *An. pharoensis* can also be prevalent across landscapes in the south (43). These diverse vector species and their varied bionomics can hamper vector control efficacy. For example, exophilic and exophagic behaviors that limit exposure to ITN and IRS insecticides, plus increasing insecticide resistance among these vectors due to exposure from both agriculture and malaria vector control efforts, may be hampering the success of the limited vector control tools available (44).. The complexity of parasite transmission from these diverse vectors also likely fosters malaria risk. For example, malaria risk increases with vector density and blood feeding rates among persons with low ITN use (45), and infection intensity and high MOI in different vector species can also drive differential malaria risks or infections with unique genotypes (16, 46-49) To develop new malaria control tools that might better control malaria in Burkina Faso, we have conducted cluster-randomized control trials in the southwestern Diebougou district to test if ivermectin mass drug administrations (MDA) can reduce malaria incidence. Ivermectin is a widely used endectocide that exhibits mosquitocidal activity (50). The drug's strong safety

 profile in humans and broad-spectrum anti-parasitic effects has allowed for its use in MDA to control neglected filarial diseases (51), and ongoing efforts to test its ability to reduce the

- survival of malaria vectors and limit malaria transmission (52-57).The first trial in Burkina Faso,
- termed Repeat Ivermectin Mass Drug Administrations for control of Malaria (RIMDAMAL), was conducted from July to November in 2015 and evaluated repeated low dose ivermectin MDA
- given at 3-week intervals in treatment clusters compared to a single MDA in control clusters
- (58), while the second trial, termed RIMDAMAL II, occurred in the same region over two
- consecutive rainy seasons (from July to November in both 2019 and 2020) and evaluated high
- dose ivermectin or placebo MDA given monthly (59). Additionally, in RIMDAMAL II, MDAs were
- operationally paired with SMC distribution to children 3-59 months old in all clusters, which was
- first implemented in the study area in 2018, in between the time of the two RIMDAMAL trials.
- The RIMDAMAL trials are among several other cluster-randomized control trials that have
- tested or are in the process of testing if ivermectin MDA can reduce malaria incidence or
- parasite prevalence among participants in treated communities (60-62).
- 
- The outcomes of the RIMDAMAL trial have been published, and the primary and secondary
- outcomes of the RIMDAMAL II trial will be presented elsewhere. In the process of analyzing the
- parasite and vector samples collected from these trials, we observed noticeable differences in
- the prevalence of different parasite species' infecting participants between the first and second

trial, some of whom participated in both trials. Most notably, in RIMDAMAL II, we observed

significant associations of specific vector species with different *Plasmodium* species that are

suggestive of differences in vector competence and/or vectorial capacity for certain parasite

species. In sub-Saharan Africa (SSA), despite *Pf* being the species most frequently detected

- and responsible for the majority of clinical cases (63), *Po* and *Pm* can significantly contribute to
- malaria epidemiology and have been observed to occur at high prevalence in parts of several
- countries (18, 19, 21, 64-73) or increasing in prevalence over longitudinal studies within a country (20). The data presented here shed light on vector-parasite interactions that may
- influence malaria epidemiology observations in these and other studies.
- 
- 

#### **Results**

#### **Organization and timelines surrounding the RIMDAMAL trials**

 The health district of Diebougou is in the southwest region of Burkina Faso in Bougouriba 147 province. The district has been conducting yearly MDA with single dose ivermectin (150 µg/kg) and albendazole (400 mg/kg) in all its communities for more than a decade to control onchocerciasis and lymphatic filariasis. The RIMDAMAL trial was conducted during the 2015 rainy season in 8 clusters (villages) in the health district, while the RIMDAMAL II trial was conducted during the 2019 and 2020 rainy seasons in 14 clusters of the district. Trial designs,

cluster selection and allocation in both trials are described elsewhere (58, 59). Briefly, in both

trials, clusters were randomized 1:1 between the treatment and control arms, and the trial

organizations and treatments and controls were different, however four clusters were common

 among the two trials (Table 1). In RIMDAMAL, repeated low dose ivermectin MDA (single oral dose, 150 µg/kg) was given at 3-week intervals in treatment clusters and compared to a single

- MDA at the start of the trial in control clusters, while the RIMDAMAL II trial occurred over two
- consecutive rainy seasons and repeated high dose ivermectin MDA (1 oral dose daily for 3
- days; 300 µg/kg) was given at 1-month intervals in treatment clusters compared to placebo
- MDA on the same schedule in control clusters. Furthermore, in RIMDAMAL II, MDA was
- operationally paired with SMC distribution to children between 3-59 months old in all clusters,
- which was instituted as national policy starting in 2017. A third, unrelated, cluster randomized trial called the REACT trial was conducted from 2016-18 by a few of the authors, which had one
- trial arm including ivermectin treatment of cattle, goats and sheep in the 2017 rainy season and
- occurred in villages of the Diebougou health district that were not part of the RIMDAMAL II trial
- (74, 75). District ITN distributions occurred in 2016 with standard pyrethroid-based nets, and at
- the end of 2019 (between October 29-November 2) with new dual-chemistry (alpha-

168 cypermethrin and chlorfenapyr) Interceptor<sup>®</sup> G2 nets to better control insecticide-resistant

malaria vectors. An analysis of Normalized Difference Moisture Index (NDMI), a measure of

vegetation moisture content and indicator of land surface wetness, across the study areas from

2015-2020 revealed marked interannual variation as well as variation between clusters (Figure

172 1). Overall, the 2015 RIMDAMAL trial was conducted during a drier rainy season of those

analyzed for the study area, while both rainy seasons of RIMDAMAL II (2019 and 2020) were

relatively wet (Figure 1). NDMI was selected for analysis because it provides information on

both temporal precipitation and landscape heterogeneity which may correspond to differences in

larval habitat abundance (76).





179

#### 180 **Differences in the prevalence of** *Plasmodium* **species between participants of the**  181 **RIMDAMAL and RIMDAMAL II trials.**

182 The prevalence of blood smear slides from the 2015 RIMDAMAL trial that were positive by

183 microscopy for *Plasmodium* spp. and for different *Plasmodium* species was previously reported,

184 as was the multiplicity of infection and molecular force of infection in *Pf* positives (58). Here we

185 report data using molecular analyses on 90 archived blood samples taken from 24 children

186 aged 0-5 years (split equally from 2 clusters in each arm) who had a fever or history of fever in

187 the prior 24 hours. Of those, 39% (35/90) of tested samples were positive for *Plasmodium* 

188 species and all were *Pf* mono-infections. Overall, 71% (17/24) of these tested children had a

189 molecularly confirmed parasitemia at least once during the trial (Table 2).

190

191 In contrast, in the RIMDAMAL II trial, infections with multiple different *Plasmodium* species were

192 commonly detected in human dried blood spots from 70 randomly chosen RIMDAMAL II

193 participants (split equally from 3 clusters in each arm, and between age grouping and sex) from

194 our cross-sectional cohort (3 villages per arm) sampled over 2 seasons (2019-2020) (Table 2).

195 Of the 405 samples tested, 56% (225/405) were positive for *Plasmodium* species, and of these

196 72% (161/225) were *Pf* mono-infections and 28% (64/225) were *Pf*-mixed or non-falciparum

197 infections (12% (27/225) *Pf+Pm* co-infections, 5% (12/225) *Pm* mono-infections, 5% (12/225) *Pf* 

198 *+ Po* co-infections, 2% (4/225) *Po* mono-infections, 0.4% (1/225) *Pf + Pv* co-infections, and 3%

199 (7/225) *Pf+Po+Pm* infections). Children 0-5 years old (who took SMC in the trial) more often had

200 negative blood samples over the trial period relative to participants  $\geq 6$  years old (61% vs. 34%;

201 P < 0.0001) and tended to less often be infected with at least one non-falciparum species over

202 the trial period relative to participants  $\geq 6$  years old (56% vs. 33%; P = 0.0871). Across all age

203 groups, most non-falciparum infections were detected in one or two cross-sectional blood

204 samples obtained from individuals throughout the trial period (Figure 2).

205



206

#### 207 *Anopheles* **speciation and blood meal analysis**

208 RIMDAMAL entomology data were previously reported (58). Briefly, 2,801 mosquitoes were

209 captured via indoor aspirated of which 99% (2,784/2,801) were morphologically identified as *An.* 

210 *gambiae* s.l. These were blood fed mosquitoes that were separated into 1) head+thorax tissue

211 that were previously homogenized and used in sporozoite ELISA assays to detect *Pf*

- 212 circumsporozoite (CSP) protein, and into 2) bloodfed abdomens that were squashed onto filter
- 213 papers cards but then used in other experiments.
- 214

215 In RIMDAMAL II, a total of 7,942 anopheline mosquitoes were collected (2019, n = 5,827; 2020,

216 n = 2,115) of which the majority were indoor-captured blood-feds that were held in assays to

217 measure their survival over time. Morphological identification determined the majority to be *An.* 

218 *gambiae* sensu lato (s.l.) (85%; 6,745/7,942), with approximately twice the number captured in 219 2019 (n = 4,679) as compared to 2020 (n = 2,066). The remainder were *An. funestus* group

220 mosquitoes (15%; 1,197/7,942) of which 96% (1,148/1,197) came from 2019. A subset of *An.* 

221 *gambiae* s.l. mosquitoes were further speciated using molecular methods (n= 354). The majority

222 were identified as *An. gambiae* (79.4%), followed by *An. coluzzi* (15.5%) and *An. arabiensis* 

223 (5.1%). Similarly, a subset of *An. funestus* group mosquitoes were further speciated (n = 251)

224 and the majority were identified as *An. funestus* (96.4%), while a small portion were identified as 225 *An. rivulorum* (3.2%) and *An. leesoni* (0.4%).

226

227 Blood meal analysis was performed on bloodfed mosquito abdomens from a subset of *An.* 

228 *gambiae* s.l. and *An. funestus* complex mosquitoes (n = 171 and 64, respectively). Human

229 blood meals were detected in most samples from both *An. gambiae* s.l. (81%) and *An. funestus* 

230  $(68\%)$  (P = 0.0559). Cattle blood meals were the next most abundant but were significantly

231 more prevalent in *An. funestus* (23%; 15/64) than in *An. gambiae* s.l*.* (6%; 11/171) (P = 0.0006).

232 Dog, goat, and pig blood meals were detected in both mosquito species, but were uncommon

233 (Figure 3).

234

# **Prevalence of** *Plasmodium* **parasites species detected in bloodfed and unfed mosquito**

# **head-thorax tissues from both trials.**

- In RIMDAMAL, the overall sporozoite rate over the intervention period and across arms was
- 4.8% (62/1759; *An. gambiae* s.l. only, head-thoraxes tested by CSP-ELISA) (Table 3).
- 



 From RIMDAMAL II, a total of n = 2,777 mosquito head-thorax samples (n = 2,528 *An. gambiae*  s.l and n = 249 *An. funestus*) were screened for *Plasmodium* sporozoites using species-specific

243 gPCR. The overall sporozoite rate over the intervention period and across arms was 5.8 % (n =

160/2,777). In *An. gambiae* s.l. the overall sporozoite rate across arms was 4.8 % (n =

122/2528) and the most common *Plasmodium* species of sporozoites detected among positives

was *Pf* mono-infections (65%; 79/122), followed by *Po* mono-infections (25%; 31/122), *Pm* 

 mono-infections (8%; 10/122), and only two mixed species infections (both *Pf+Po* co-infections; Figure 4c). In contrast, *An. funestus* had a significantly higher overall sporozoite rate over the intervention period than *An. gambiae* s.l. (15.3%; 38/249; P < 0.0001). Also, in contrast to *An.* 

 *gambiae* s.l., the most prevalent sporozoite species detected among positives of *An. funestus* was *Po* (63.2%;24/38), followed by *Pf* and *Pm*, both at 18.4% (7/38 each) (Figure 4f). Thus, in the RIMDAMAL II trial, the *Pf* sporozoite rate in *An. gambiae s.l.* was significantly greater than in *An. funestus* (P <0.0001), and the *Po* sporozoite rate in *An. funestus* was significantly greater than in *An. gambiae s.l.* (P <0.0001) from mosquitoes captured in the same villages and houses over the same dates. Furthermore, while the overall sporozoite rates and those from *An. gambiae s.l.* captured in clusters from treatment or control arms were not significantly different 257 from one another, sporozoite rates were significantly higher  $(\sim2$  fold) in the control arm relative

- to the intervention arm for *An. funestus* (P = 0.0416; Table 3).
- 

#### **Prevalence of** *Plasmodium* **parasites species detected in bloodfed and unfed mosquito abdomens in RIMDAMAL II**

To better understand the observed differences in sporozoite rates between species and

treatment arms in RIMDAMAL II, we examined a portion of the stored bloodfed and unfed

abdomen samples from each mosquito species and from those that were either sporozoite-

positive or sporozoite-negative. Of the 264 *An. gambiae* s.l. bloodfed abdomens tested, 75%

- (198/264) were positive for at least one *Plasmodium* species (Figure 4a). Approximately half of
- positives (47%; 93/198) contained parasites of only one species and most often this was *Pf*.
- However, nearly as many (41%; 81/198) contained mixed parasites consisting of *Pf* plus one or
- more non-falciparum species. In contrast, of the *An. funestus* bloodfed abdomens tested, a

significantly lower proportion were *Plasmodium*-positive (52.8%; 47/89; P = 0.0002) (Figure 4d),

with the majority (87.2%; 41/47; P < 0.0001) containing parasites of a single species of either

*Pf*, *Po* or *Pm.* Overall *Plasmodium* spp. prevalence in blood fed abdomens was modestly higher

in sporozoite-positive versus sporozoite-negative mosquitoes, regardless of mosquito species

- (Figure 5). Similarly, mosquitoes captured from treatment arm clusters had a modestly lower
- prevalence of *Plasmodium* spp. than those captured from control arm clusters (Figure 6).
- 

Most unfed abdomens tested negative for parasites (Figure 4b & 4e), in contrast to the blood

fed abdomens of the same species (Figure 4a & 4c). Furthermore, *Plasmodium* species

 prevalence in these unfed abdomens were higher than, but reflective of, the sporozoite-positive head-thoraxes of the different mosquitoes in that only mono-infections were detected. *Pf* and *Po*

infections were approximately equal among the unfed abdomens of these mosquitoes, but *Pm*

infections of unfed abdomens were only detected in *An. funestus* (Figure 4b & 4e)*.*

## **Discussion**

The results presented suggest that malaria epidemiology at the study site appears to have

changed over a six-year period whereby non-falciparum species have become prevalent,

particularly as mixed infections with *Pf*. The data also suggest that vectors species have

differential competence for spreading non-falciparum infections, which may be one novel driver

 explaining changes in malaria species epidemiology. Unfortunately, standard malaria surveillance performed by the national health authorities, and most other malaria studies in the

country over the last decade, have focused on tackling the burden of *Pf,* and molecular data on

the prevalence of non-falciparum species in Burkina Faso is largely lacking. One other

published study, however, similarly reported an increase in non-falciparum infections from 2007-

2010 in central-west Burkina Faso in, but entomological indices were not reported (20).

 In addition to entomological factors, anthropogenic factors regarding diagnostics and treatment algorithms have likely driven or influenced the epidemiologic changes observed. Most notably, current POC diagnostics suffer from relatively low sensitivity, requiring peripheral densities of ~100-500 parasites/ $\mu$ L for detection, yet most non-falciparum species tend to maintain lower parasitemias that go undetected (17, 18, 23, 24, 77-79). In addition, while microscopy has the advantage of morphologic-based speciation, this is challenging in practice, particularly in the presence of mixed species infection. With regards to RDTs, nearly 80% of RDTs currently procured in sub-Saharan Africa detect only *Pf-*specific HRP-2 (80-82). While a second less widely available RDT detects both *Pf*HRP-2 and pan-*Plasmodium* LDH (83-86), its sensitivity is also low at densities below 1000/μL (25, 87-89).Treatment and prevention guidelines also likely impact species prevalence, as most strategies are explicitly geared towards reducing the *Pf* burden. In West Africa, the implementation of SMC, including at the site of the RIMDAMAL trials in 2018, has proven to have significant impacts on *Pf* incidence in children, and although it is anticipated that SP-AQ has activity against non-falciparum species, its precise impact on these other species has not been investigated (90-96). Similarly, the impact of ACTs on non-

falciparum species is less well studied, and the near-complete lack of usage of 8-

aminoquinolines directed at the dormant liver stages of *Po* and *Pv* in Africa results in a

persisting reservoir of infection even if blood-stage therapy is initiated. In a 2-year study of

 malaria prevalence in Niger during and after SMC distributions, cross sectional microscopy surveys detected *Pf* alone in the high and low seasons of year 1, but subsequently detected mixed- and mono-infections with *Po* and *Pm* in year 2 (97). In our RIMDAMAL trials, incidence in 0 to 5 year olds dropped approximately 80% between 2015 and 2019 (58) (ClinicalTrials.gov: NCT03967054), presumably due to SMC commencing in 2018, but parasite prevalence remained exceedingly high in both trials suggesting a limited ability of SMC to affect parasite prevalence in this high transmission setting. Malaria incidence among the child cohort in RIMDAMAL II dropped further in 2020 across both arms, which is likely connected to the activity of dual chemistry nets distributed in both trial arms. It is also possibly that an increase in non- *falciparum* parasite species at the field site may have contributed to the overall reduction in malaria incidence via our active case detection procedures between the two RIMDAMAL trials given that the pyrogenic thresholds of non-*falciparum* species are likely to be lower than *Pf* (98) from considerably lower parasitemias and shorter durations of patent infections (23, 24, 99, 100).

 The abundance of *An. funestus* in RIMDAMAL II during the 2019 rainy season was unexpected considering our data from previous seasons (39, 41, 58). Typically, this vector increases at the very end of the rainy season and persists through the early, 'cold' dry season (late October - February), a time when *An. gambiae* s.l. populations fall dramatically. Its presence is connected to more permanent water sources with emergent vegetation (42, 101) that remain following the cessation of the seasonal rains. *An. funestus* was highly prevalent at the study site in human landing catches performed during dry season sampling between 2017-8 during the REACT trial (75). Its abnormally high density so early in the year in 2019 may be related to the wetter-than- average rainy season (Figure 1) where it could take advantage of the more abundant, possibly deeper water breeding sites across the landscape due to the excess water. Regardless, the opportunity to catch both *An. gambiae* s.l. and *An. funestus*, especially the blood feds, in the same households over the same timeframes allowed for novel insights into potential differential vector competence between *An. gambiae* and *An. funestus* in our area.

 The tested blood fed abdomens of both mosquito species would be expected to contain a mix of newly ingested parasites (both asexual forms and gametocytes) from mostly human blood meals that were taken the night prior to capture, as well a smaller proportion of developing early sporogonic stages in and on the midgut tissues of mosquitoes that were infected from an earlier blood meal. The unfed abdomens, being from host-seeking mosquitoes captured in the same households as the blood feds, provided a measure of the proportion of mosquitoes already containing those developing sporogonic stages, which was 21.6% for *An. gambiae* s.l. and 38.2% for *An. funestus*. Considering the proportions of negative abdominal tissues between blood feds and unfeds, the data suggest *An. gambiae* s.l. are exposed to parasites upon blood feeding nearly twice as often as *An. funestus*, likely from higher human biting rates that we observed from this mosquito, and potentially also from a higher propensity to blood feed on multiple people over a single night (102). The data also show that mixed-parasite species blood meals, which we surprisingly observed often in the human samples too, were present nearly five times as often among *An. gambiae* s.l. than *An. funestus*, but mixed infections were not detected in unfed abdomens of either mosquito species, and only detected twice in thoraxes as

 sporozoites. Dividing the unfed abdomen infection rates by the blood fed abdomen parasite rate can provide a rough approximation of successful midgut infection in the wild for both mosquito species, which was only 29% of the time for *An. gambiae* s.l. but approximately 72% of the time for *An. funestus*. Examination of infected unfed abdomens compared to sporozoite infections in the positive head+thorax tissues suggests that successful parasite development from early to late sporogonic forms may be similarly more restrictive in *An. gambiae* s.l. (22%) than in *An. funestus* (40%). Lastly, the differences observed in the prevalence of different *Plasmodium* species across the tissues of the two mosquitoes is notable. These data suggest that while *An. funestus* was less often exposed to parasites during blood feeding, the exposure was more often as mono-infections and parasite infection was more often successful. Furthermore, *An. funestus* was preferentially infected with *Pm* or *Po*, but complete sporogonic development to sporozoites more often favored *Po*. In contrast, *An. gambiae* s.l. captured at the same timepoints and from the same households was more often exposed to parasites during blood feeding and up to 40% may have been mixed-infection exposures, but parasite infections were less successful. Furthermore, midgut infections in *An. gambiae* s.l. (unfed abdomens) were nearly always of a single parasite species which was typically *Pf* and *Po,* but *Pf* more often successfully developed into sporozoites.

 Given these are observational entomological and human data, there are several non-mutually exclusive hypotheses that could explain the findings. Most obviously, data may reflect true vector competence differences of mosquito species for different parasite species, such as parasite exflagellation, fertilization or sporogonic development being enhanced for *Po* in *An. funestus*, or the inverse whereby these are inhibited for *Pm* and *Po* in *An. gambiae*, perhaps via innate immune targeting mechanisms (103). This may be an observation of emergent co- speciation between vector and parasite species. Parasite species sporogony competition, either directly or for resources in the mosquito, may also contributing to preferential vector competence outcomes in one mosquito species over the other (104-108). Lastly, factors influencing vectorial capacity may also help explain some of these observations. The *An. funestus* we captured blood fed more often on cattle, which may explain some of the parasite prevalence data in blood fed abdomens, but another possibility is that *An. funestus* preferentially blood fed on human hosts with different parasite species relative to *An. gambiae*, possibly due to a preference for certain attractive odors given off by the infected host dependent on the parasite species they were infected with (109). Some of the results may also be explained by differences in vector blood meal sizes or vector lifespans, such as if most of the *An. funestus* mosquitoes are longer-lived and therefore more likely to have non-falciparum sporozoites which develop less rapidly than *Pf*, or mortality in the field due to certain combinations of parasite and vector, for example if *Pm* sporogonic development increases *An. gambiae* s.l. mortality. We are not aware of previous field reports on co-speciation or preferential sporogonic development of certain *Plasmodium species* over others in different species of vector anophelines. Molecular detection of *Plasmodium* in mosquitoes captured from the field in African settings remains relatively rare due to the costs of performing qPCR on numerous individual mosquito samples with different molecular probes. More often ELISA assays are used to save costs, but these are often only used with antibodies to *Pf* or *Pv* alone (110) and are relatively insensitive and prone to false positives when compared to molecular analyses (111-113). Also, for molecular analyses

- of mosquitoes, the most efficient molecular targets are also still being compared (114, 115), as
- are the dissection methods to ensure the fewest false positives (116). We chose to dissect at
- the junction of the midgut and abdomen, however, the large differences in parasite prevalence
- between blood fed abdomens compared to unfed abdomens and head+thoracies suggests our
- analyses was not overly biased from parasite contamination across mosquito tissues.
- Regardless, this was a comparative analysis between mosquito species.
- 

 Importantly, this study has several limitations. Foremost, these longitudinal data are confined to a single field site and must be tested to determine their generalizability. It is possible that the

- 
- results are partially related to the ivermectin or other intervention activities occurring at the site. Regarding the human data, we had limitations from our more limited testing of archived samples
- from the RIMDAMAL trial, including that the blood samples tested were only from symptomatic
- children. Retrospective molecular analysis of mosquito tissues from the RIMDAMAL trial were
- also not possible due to the samples having been used in prior assays. Follow-up blood
- sampling and testing should be performed at the site to determine if the change in prevalence
- from *Pf* to more non-*falciparum* species persists or increases over time, and if non-*falciparum*
- infections are correlated with presence of *An. funestus* or increased rainfall during the wet
- season in other areas. While the entomological data are a measure of natural infection
- outcomes, the analyses are associative being based on observational data alone and so they
- should be validated using mosquito feeding assays with the blood from infectious participants.
- 

## **Conclusion**

- The data presented here show that malaria parasite species prevalence in humans changed
- dramatically in the Diebougou health district in southwest Burkina Faso over the period
- bracketing the two RIMDAMAL trials occurring five years apart, and when SMC was initiated at
- 427 the site in between the two trials. The parasite species changed from almost exclusively being
- *Pf* to a high prevalence of non-falciparum species mixed with *Pf* or occurring alone.
- Furthermore, evidence suggests that non-falciparum species were preferentially transmitted by
- *An. funestus* while *Pf* was preferentially transmitted by *An. gambiae* s.l. These formative studies
- should be followed up with more rigorous testing of the hypotheses regarding vector
- competence or vectorial capacity differences for *Plasmodium* parasites between the different
- mosquito species and may explain the changing malaria epidemiology in areas of sub-Saharan
- Africa where a diversity of anopheles vectors exist or are in flux.

#### **Methods**

## **Study area, experimental design, and adult mosquito collection**

- The Diebougou health district in southwestern Burkina Faso experiences a single long rainy
- season from approximately June-November (39). The RIMDAMAL trial spanned one rainy
- season (July-November) in 2015, and RIMDAMAL II spanned rainy seasons (July-November) in
- two consecutive years, 2019 and 2020 and both were conducted in this health district. Detailed
- information about both trials is available elsewhere (58, 59). Briefly, in RIMDAMAL, 8 village
- clusters were studied and 4 were randomized to the intervention arm consisting of 6 ivermectin
- MDAs (single dose of 150 µg/kg) for eligible participants every 3 weeks over one season, while
- the other 4 were randomized to the control arm consisting of a single ivermectin MDA (single

 dose of 150 µg/kg) for eligible participants at the beginning of the season. In RIMDAMAL II, 14 447 village clusters were studied and 7 were randomized to the intervention arm consisting of 4 ivermectin MDA (3 consecutive daily doses of 300 µg/kg) for eligible participants once per month over 4 months of the season, while the other 7 were randomized to the control arm consisting of placebo administered in the same manner. To estimate spatiotemporal variations in land surface wetness in the study area, Normalized Difference Moisture Index (NDMI), a measure of vegetation moisture content, was assessed from 2015-2020. NDMI was measured from Landsat 8 Level 2, Collection 2, Tier 1 satellite images at 30-m resolution. Satellite images were obtained from the rainy seasons (May to October) and median NDMI calculated for each year from near infrared and short-wave infrared bands after cloud masking in Google Earth Engine.

#### 

 *Anopheline* mosquito sampling in both trials was performed similarly, in 8 households from each village in RIMDAMAL and from 8 households in each of 3 villages per arm in RIMDAMAL II,

- whereby most mosquitoes captured were resting indoor blood feds and aspirated from walls and
- ceilings in the mornings, and additional capture of host-seeking mosquitoes was performed
- using light traps located a single centrally located house per village placed indoors next to a
- person sleeping under a bed net and outdoors next to a person sleeping in a tent. In 464 RIMDAMAL, mosquito collections occurred on the  $2<sup>nd</sup>$  week follow each MDA, and in
- 465 RIMDAMAL II on the 1<sup>st</sup> and  $3<sup>rd</sup>$  weeks following each MDA. Participants' blood from these same
- households was also serially sampled across the intervention periods to allow linking of
- parasitology and entomology outcomes. After collection, mosquitoes were morphologically
- identified in the field station as either *An. gambiae* s.l., *An. funestus* complex, or other species,
- and molecular analyses were performed subsequently in laboratories.

#### 

## **DNA extraction from dried human blood spots**

 Dried blood spots (DBS) on filter paper cards were made in RIMDAMAL from active case detection (ACD) cohort children whose blood was sampled during febrile episodes occurring during the trial. DBS from 24 of these randomly chosen participants who were living in the 4 villages that were also enrolled in RIMDAMAL II (Table 1; KP, TJ, DK, TG) and which were also sampled for mosquitoes were tested for *Plasmodium* species. In RIMDAMAL II, serially collected DBS were collected from participants of all ages from households that were also sampled for mosquitoes, and DBS from 100 of these randomly chosen participants were tested for *Plasmodium* species. DNA was extracted from 3mm hole punches of each DBS by incubating them overnight in a 60°C shaking incubator with PBS and proteinase K and the supernatant process with a Mag-Bind Viral DNA/RNA 96 kit (Omega Bio-Tek) using the KingFisher Flex Magnetic Particle Processor (Thermo Fisher Scientific). DNA was eluted in 30

- μL of nuclease-free water and stored at -80° C prior to testing.
- 

## **DNA extraction from RIMDAMAL II mosquito tissues**

Female *Anopheline* head+thoraces stored in RNALater® (Thermo Fisher Scientific) were

- removed from tubes and blotted on absorbent paper to remove excess liquid. Samples were
- then individually placed in new tubes with 300 μL mosquito diluent containing 20% of FBS, 100
- μg/mL of streptomycin, 100 units/mL of penicillin, 50 μg/mL gentamicin, and 2.5 μg/mL

 fungizone in PBS. Samples were homogenized by a single zinc-plated, steel 4.5 mm bead for 491 1.5 minutes at 24 Hz before being centrifuged for 5 minutes at 14,000 x g at 4°C. DNA was extracted from all samples using the Mag-Bind Viral DNA/RNA 96 kit (Omega Bio-Tek) using the KingFisher Flex Magnetic Particle Processor (Thermo Fisher Scientific). DNA was eluted in 30 μL of nuclease-free water and stored at -80°C. Abdomen samples were placed in 2.0 mL tubes with one 4-5 mm steel bead, TL buffer, and proteinase K solution provided by the Mag Bind Blood and Tissue Kit HDQ 96 kit (Omega Bio-Tek). Each sample was homogenized (50 oscillation for 5 minutes), centrifuged (8,000 rpm for 30 seconds), and incubated in a 56°C dry bath overnight. The next day, homogenates were extracted using a KingFisher™ Flex Purification System (Thermo Fisher Scientific). DNA was eluted in 100 uL of nuclease-free water and yields were quantified using a Nanodrop device (ThermoFisher Scientific) to determine the success of extraction. Once quantified, samples were stored at -80°C until further analysis.

#### *Anopheles* **speciation**

 Morphological identification of wild-caught *An. funestus* and *An. gambiae* s.l*.* mosquitoes was done using standard taxonomic key in the field (117, 118). In a MiniAmp PlusThermocycler, *An. gambiae* s.l*.* were further speciated following PCR assay which amplified a region of the intergenic spacer 2 (119) to identify *An. gambiae*, *An. coluzzii* and *An. arabiensis*. To further speciate mosquitoes belonging to the *An. funestus* complex, a portion of the ITS2 gene was amplified following the method of Koekemoer et al. (120), and subsequently sequenced. The DNA sequences were aligned in Mesquite (121), and the *Anopheles* species was determined by comparing the sequences with those found in the GeneBank nucleotide database.

#### *Plasmodium* **detection in both human and mosquito samples**

 To detect the presence of *Pf, Po, Pm* and *Pv* in the head+thorax and/or abdomen tissues, two real-time PCRs were done. *Pf* DNA was detected using the assay described by Hoffman et al. (122), which detects *P. falciparum* DNA in mosquito tissues by amplifying the *var* gene acidic terminal sequence (*var*ATS). *Po, Pm* and *Pv* were detected following the protocol described by Phuong et al. (123), which targets the 18S rRNA gene. *Pf* samples that amplified at or before 36 cycles and showed a logarithmic amplification curve were interpreted as positive. The positive controls for *Pf* were DNA from *Plasmodium*-infected DBS generated from *in vitro* culture at various ranges of parasitemia placed on filter paper, from which 3 mm punches were placed in PCR tubes with 70 μL Rapid Extraction Solution (Thermo Fisher Scientific) and rocked overnight 524 at  $4^{\circ}$ C and the DNA was purified using the same procedure as described for head+thorax. Negative controls were DNA extracts from malaria-negative DBS. *Po, Pm* and *Pv* were detected following the protocol described by Phuong et al. (123), which involved using species-specific forward primers and probes targeting the 18S rRNA gene. *Po* was identified using a probe labeled with VIC at the 5' end and a minor groove binding quencher at the 3' end. *Pv* was detected using a probe labeled with TAMRA at the 5' end and a BHQ-2 quencher at the 3' end. *Pm* was identified using a probe labeled with FAM at the 5' end and a minor groove binding quencher at the 3' end. The same reverse primer was used for all species identification. Nuclease-free water served as the negative control, while linearized, clean DNA from the plasmid clones (MRA numbers 177–180; BEI Resources, NIH, NIAID) acted as both positive

 controls. All head+thorax samples that showed logarithmic amplification at or before 36 cycles were interpreted as positive. All PCR reactions were performed in a QuantStudio 3 real-time PCR instrument (Thermo Fisher Scientific).

## **Blood meal analysis**

 A conventional PCR followed by a 1.5% electrophoresis gel was done to analyze the host blood meal of mosquito abdomen samples, following the methods described by Kent et al. (124), which amplifies a region of the cytochrome b mitochondrial gene and includes primers to identify blood meals from dog, human, cow, pig, and goat host species. The electrophoresis gel ran at

- 90 volts for 45 minutes and was imaged on a BIO-RAD ChemiDoc MP Imaging System for analysis.
- 

## **Statistical analysis**

Data was analyzed on GraphPad Prism or R (R-project.org). Chi-square tests and Fisher's

exact test were performed, depending on the number of variables. Chi-square test for trend

tests for linear trends between variables, while the Fisher's exact test tests for association

between variables, and both assess the chances of observing the trend/association in random

sampling (GraphPad Prism Version 9.3.1). A P value less than 0.05 was interpreted as

- statistically significant.
- 

## **Data Availability**

 All RIMDAMAL II data will be deposited in ClinEpiDB.org and be available for analysis and download under the terms of set by the website.

- 
- 

## **Figures**

- 
- 



592 Collection 2, Tier 1) were obtained from the rainy seasons (May to Oct) and median clusters (outlined in black) **B)** Temporal variation in mean study site NDMI. Dashed line indicates overall median value. **C)** Spatial variation in NDMI at each cluster (all NDMI calculated for each year. **A)** Map of relative wetness at the study site and years).

<del>oor</del>

 













#### **References**

1. World Health Programme. World Malaria Report 2023. Geneva: 2023.

 2. Institut National de la Statistique et de la Démographie (INSD) PdAaD, Sanitaire (PADS) PNdLclPPeI. Enquête sur les indicateurs du paludisme au Burkina Faso. Rockville, Maryland, USA: 2018.

3. Yaro JB, Tiono AB, Ouedraogo A, Lambert B, Ouedraogo ZA, Diarra A, Traore A,

Lankouande M, Soulama I, Sanou A, Worrall E, Agboraw E, Sagnon N, Ranson H, Churcher

TS, Lindsay SW, Wilson AL. Risk of Plasmodium falciparum infection in south-west Burkina

 Faso: potential impact of expanding eligibility for seasonal malaria chemoprevention. Sci Rep. 2022;12(1):1402. doi: 10.1038/s41598-022-05056-7. PubMed PMID: 35082312; PMCID:

PMC8791962.

 4. Sangare I, Ouattara CA, Soma DD, Soma D, Assogba BS, Namountougou M, Tougri G, Savadogo LB. Spatial-temporal pattern of malaria in Burkina Faso from 2013 to 2020. Parasite Epidemiol Control. 2022;18:e00261. doi: 10.1016/j.parepi.2022.e00261. PubMed PMID: 35859938; PMCID: PMC9289732.

 5. Bationo C, Cissoko M, Katile A, Sylla B, Ouedraogo A, Ouedraogo JB, Tougri G, Kompaore SCB, Moiroux N, Gaudart J. Malaria in Burkina Faso: A comprehensive analysis of spatiotemporal distribution of incidence and environmental drivers, and implications for control strategies. PLoS One. 2023;18(9):e0290233. doi: 10.1371/journal.pone.0290233. PubMed PMID: 37703223; PMCID: PMC10499254.

- 6. US Presidents Malaria Initiative. U.S. President's Malaria Initiative Burkina Faso Malaria Operational Plan FY 2024. U.S. President's Malaria Initiative 2023.
- 771 7. United Nations Development Programme. Human Development Report 2021-22:<br>772 Uncertain Times, Unsettled Lives: Shaping our Future in a Transforming World. New Yor Uncertain Times, Unsettled Lives: Shaping our Future in a Transforming World. New York: 2022.
- 8. Rouamba T, Nakanabo-Diallo S, Derra K, Rouamba E, Kazienga A, Inoue Y, Ouedraogo EK, Waongo M, Dieng S, Guindo A, Ouedraogo B, Sallah KL, Barro S, Yaka P, Kirakoya- Samadoulougou F, Tinto H, Gaudart J. Socioeconomic and environmental factors associated with malaria hotspots in the Nanoro demographic surveillance area, Burkina Faso. BMC Public Health. 2019;19(1):249. doi: 10.1186/s12889-019-6565-z. PubMed PMID: 30819132; PMCID: PMC6396465.

 9. Guglielmo F, Ranson H, Sagnon N, Jones C. The issue is not 'compliance': exploring exposure to malaria vector bites through social dynamics in Burkina Faso. Anthropol Med. 2021;28(4):508-25. doi: 10.1080/13648470.2021.1884185. PubMed PMID: 33970705; PMCID: PMC7613283.

 10. Allan-Blitz LT, Goldfine C, Erickson TB. Environmental and health risks posed to children by artisanal gold mining: A systematic review. SAGE Open Med. 2022;10:20503121221076934. doi: 10.1177/20503121221076934. PubMed PMID: 35173966; PMCID: PMC8841918.

 11. Boukaré B. The development impact of "gold rushes" in Mali and Burkina Faso: the multifaceted effects of migration on artisanal gold mining sites. In: Fargues F, M. Rango, E. Börgnas and I. Schöfberger, editor. Migration in West and North Africa and across the Mediterranean. Geneva2020.

791 12. Mueller I, Schoepflin S, Smith TA, Benton KL, Bretscher MT, Lin E, Kiniboro B,<br>792 Zimmerman PA, Speed TP, Siba P, Felger I. Force of infection is key to understanding Zimmerman PA, Speed TP, Siba P, Felger I. Force of infection is key to understanding the epidemiology of Plasmodium falciparum malaria in Papua New Guinean children. Proc Natl Acad Sci U S A. 2012;109(25):10030-5. Epub 2012/06/06. doi: 10.1073/pnas.1200841109.

 PubMed PMID: 22665809; PMCID: 3382533. 796 13. Eldh M, Hammar U, Arnot D, Beck HP, Garcia A, Liljander A, Mercereau-Puijalon O,<br>797 Migot-Nabias F, Mueller I, Ntoumi F, Ross A, Smith T, Sonden K, Vafa Homann M, Yman V, Migot-Nabias F, Mueller I, Ntoumi F, Ross A, Smith T, Sonden K, Vafa Homann M, Yman V, Felger I, Farnert A. Multiplicity of Asymptomatic Plasmodium falciparum Infections and Risk of

 Clinical Malaria: A Systematic Review and Pooled Analysis of Individual Participant Data. J Infect Dis. 2020;221(5):775-85. doi: 10.1093/infdis/jiz510. PubMed PMID: 31585009; PMCID: PMC7026891. 14. Goodwin J, Kajubi R, Wang K, Li F, Wade M, Orukan F, Huang L, Whalen M, Aweeka FT, Mwebaza N, Parikh S. Persistent and multiclonal malaria parasite dynamics despite extended artemether-lumefantrine treatment in children. Nat Commun. 2024;15(1):3817. doi: 10.1038/s41467-024-48210-7. PubMed PMID: 38714692; PMCID: PMC11076639. 15. Sondo P, Derra K, Rouamba T, Nakanabo Diallo S, Taconet P, Kazienga A, Ilboudo H, Tahita MC, Valea I, Sorgho H, Lefevre T, Tinto H. Determinants of Plasmodium falciparum 808 multiplicity of infection and genetic diversity in Burkina Faso. Parasit Vectors. 2020;13(1):427.<br>809 doi: 10.1186/s13071-020-04302-z. PubMed PMID: 32819420; PMCID: PMC7441709. doi: 10.1186/s13071-020-04302-z. PubMed PMID: 32819420; PMCID: PMC7441709. 16. Ehrlich HY, Some AF, Bazie T, Ebou CN, Dembele EL, Balma R, Goodwin J, Wade M, Bei AK, Ouedraogo JB, Foy BD, Dabire RK, Parikh S. Tracking antimalarial drug resistance using mosquito blood meals: a cross-sectional study. Lancet Microbe. 2023. doi: 10.1016/S2666-5247(23)00063-0. PubMed PMID: 37086737. 17. Mueller I, Zimmerman PA, Reeder JC. Plasmodium malariae and Plasmodium ovale-- the "bashful" malaria parasites. Trends Parasitol. 2007;23(6):278-83. doi: 10.1016/j.pt.2007.04.009. PubMed PMID: 17459775; PMCID: PMC3728836. 18. Roh ME, Oyet C, Orikiriza P, Wade M, Kiwanuka GN, Mwanga-Amumpaire J, Parikh S, Boum Y, 2nd. Asymptomatic Plasmodium Infections in Children in Low Malaria Transmission Setting, Southwestern Uganda(1). Emerg Infect Dis. 2016;22(8):1494-8. doi: 10.3201/eid2208.160619. PubMed PMID: 27434741; PMCID: PMC4982177. 821 19. Sendor R, Banek K, Kashamuka MM, Mvuama N, Bala JA, Nkalani M, Kihuma G, Atibu<br>822 J. Thwai KL, Svec WM, Goel V, Nseka T, Lin JT, Bailey JA, Emch M, Carrel M, Juliano JJ, J, Thwai KL, Svec WM, Goel V, Nseka T, Lin JT, Bailey JA, Emch M, Carrel M, Juliano JJ, Tshefu A, Parr JB. Epidemiology of Plasmodium malariae and Plasmodium ovale spp. in Kinshasa Province, Democratic Republic of Congo. Nat Commun. 2023;14(1):6618. doi: 10.1038/s41467-023-42190-w. PubMed PMID: 37857597; PMCID: PMC10587068 Abbott Laboratories, and consulting for Zymeron Corporation, all outside the scope of this study. The remaining authors declare no competing interests. 828 20. Gneme A, Guelbeogo WM, Riehle MM, Tiono AB, Diarra A, Kabre GB, Sagnon N, 829 Vernick KD. Plasmodium species occurrence, temporal distribution and interaction in a ch Vernick KD. Plasmodium species occurrence, temporal distribution and interaction in a child- aged population in rural Burkina Faso. Malar J. 2013;12:67. Epub 2013/02/21. doi: 10.1186/1475-2875-12-67. PubMed PMID: 23421809; PMCID: 3583752. 832 21. Heinemann M, Phillips RO, Vinnemeier CD, Rolling CC, Tannich E, Rolling T. High prevalence of asymptomatic malaria infections in adults, Ashanti Region, Ghana, 2018. Malar J. 2020;19(1):366. doi: 10.1186/s12936-020-03441-z. PubMed PMID: 33046056; PMCID: PMC7552528. 22. Agonhossou R, Akoton R, Lagnika H, Djihinto OY, Sovegnon PM, Saizonou HD, Ntoumi F, Wondji CS, Borrmann S, Adegnika AA, Djogbenou LS. P. falciparum msp1 and msp2 genetic diversity in P. falciparum single and mixed infection with P. malariae among the asymptomatic population in Southern Benin. Parasitol Int. 2022;89:102590. doi: 10.1016/j.parint.2022.102590. PubMed PMID: 35472441. 23. Trape JF, Rogier C, Konate L, Diagne N, Bouganali H, Canque B, Legros F, Badji A, Ndiaye G, Ndiaye P, et al. The Dielmo project: a longitudinal study of natural malaria infection and the mechanisms of protective immunity in a community living in a holoendemic area of Senegal. Am J Trop Med Hyg. 1994;51(2):123-37. doi: 10.4269/ajtmh.1994.51.123. PubMed PMID: 8074247. 24. Faye FB, Konate L, Rogier C, Trape JF. Plasmodium ovale in a highly malaria endemic area of Senegal. Trans R Soc Trop Med Hyg. 1998;92(5):522-5. doi: 10.1016/s0035- 9203(98)90900-2. PubMed PMID: 9861368.

 25. Yerlikaya S, Campillo A, Gonzalez IJ. A Systematic Review: Performance of Rapid Diagnostic Tests for the Detection of Plasmodium knowlesi, Plasmodium malariae, and Plasmodium ovale Monoinfections in Human Blood. J Infect Dis. 2018;218(2):265-76. doi: 10.1093/infdis/jiy150. PubMed PMID: 29554284; PMCID: PMC6009649.

 26. World Health Organization. Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale malaria 2016.

 27. Diabate A, Dabire RK, Kengne P, Brengues C, Baldet T, Ouari A, Simard F, Lehmann T. Mixed swarms of the molecular M and S forms of Anopheles gambiae (Diptera: Culicidae) in sympatric area from Burkina Faso. J Med Entomol. 2006;43(3):480-3. doi: 10.1603/0022-

- 2585(2006)43[480:msotmm]2.0.co;2. PubMed PMID: 16739404. 28. Fournet F, Cussac M, Ouari A, Meyer PE, Toe HK, Gouagna LC, Dabire RK. Diversity in anopheline larval habitats and adult composition during the dry and wet seasons in Ouagadougou (Burkina Faso). Malar J. 2010;9:78. doi: 10.1186/1475-2875-9-78. PubMed
- PMID: 20298619; PMCID: PMC2907872.
- 29. Wondji CS, Dabire RK, Tukur Z, Irving H, Djouaka R, Morgan JC. Identification and distribution of a GABA receptor mutation conferring dieldrin resistance in the malaria vector Anopheles funestus in Africa. Insect Biochem Mol Biol. 2011;41(7):484-91. doi:
- 10.1016/j.ibmb.2011.03.012. PubMed PMID: 21501685; PMCID: PMC3579012.
- 30. Gimonneau G, Pombi M, Choisy M, Morand S, Dabire RK, Simard F. Larval habitat segregation between the molecular forms of the mosquito Anopheles gambiae in a rice field area of Burkina Faso, West Africa. Med Vet Entomol. 2012;26(1):9-17. doi: 10.1111/j.1365- 2915.2011.00957.x. PubMed PMID: 21501199; PMCID: PMC3140611.
- 31. Namountougou M, Simard F, Baldet T, Diabate A, Ouedraogo JB, Martin T, Dabire RK. Multiple insecticide resistance in Anopheles gambiae s.l. populations from Burkina Faso, West Africa. PLoS One. 2012;7(11):e48412. Epub 2012/11/29. doi: 10.1371/journal.pone.0048412. PubMed PMID: 23189131; PMCID: 3506617.
- 32. Dabire RK, Namountougou M, Sawadogo SP, Yaro LB, Toe HK, Ouari A, Gouagna LC, Simard F, Chandre F, Baldet T, Bass C, Diabate A. Population dynamics of Anopheles gambiae s.l. in Bobo-Dioulasso city: bionomics, infection rate and susceptibility to insecticides. Parasit Vectors. 2012;5:127. Epub 2012/06/23. doi: 10.1186/1756-3305-5-127. PubMed PMID: 22721002; PMCID: 3424103.
- 33. Namountougou M, Diabate A, Etang J, Bass C, Sawadogo SP, Gnankinie O, Baldet T, Martin T, Chandre F, Simard F, Dabire RK. First report of the L1014S kdr mutation in wild populations of Anopheles gambiae M and S molecular forms in Burkina Faso (West Africa).
- Acta Trop. 2013;125(2):123-7. Epub 2012/11/07. doi: 10.1016/j.actatropica.2012.10.012. PubMed PMID: 23128044.
- 34. Niang A, Epopa PS, Sawadogo SP, Maiga H, Konate L, Faye O, Dabire RK, Tripet F, Diabate A. Does extreme asymmetric dominance promote hybridization between Anopheles coluzzii and Anopheles gambiae s.s. in seasonal malaria mosquito communities of West Africa? 888 Parasit Vectors. 2015;8:586. doi: 10.1186/s13071-015-1190-x. PubMed PMID: 26559354;<br>889 PMCID: PMC4642620.
- PMCID: PMC4642620.
- 35. Hidalgo K, Montazeau C, Siaussat D, Braman V, Trabalon M, Simard F, Renault D, Dabire RK, Mouline K. Distinct physiological, biochemical and morphometric adjustments in the malaria vectors Anopheles gambiae and A. coluzzii as means to survive dry season conditions in Burkina Faso. The Journal of experimental biology. 2018;221(Pt 6). doi: 10.1242/jeb.174433. PubMed PMID: 29378815.
- 36. Gildenhard M, Rono EK, Diarra A, Boissiere A, Bascunan P, Carrillo-Bustamante P,
- Camara D, Kruger H, Mariko M, Mariko R, Mireji P, Nsango SE, Pompon J, Reis Y, Rono MK,
- Seda PB, Thailayil J, Traore A, Yapto CV, Awono-Ambene P, Dabire RK, Diabate A, Masiga D,
- Catteruccia F, Morlais I, Diallo M, Sangare D, Levashina EA. Mosquito microevolution drives

 Plasmodium falciparum dynamics. Nat Microbiol. 2019;4(6):941-7. doi: 10.1038/s41564-019- 0414-9. PubMed PMID: 30911126; PMCID: PMC7613322.

 37. Namountougou M, Soma DD, Kientega M, Balbone M, Kabore DPA, Drabo SF, Coulibaly AY, Fournet F, Baldet T, Diabate A, Dabire RK, Gnankine O. Insecticide resistance mechanisms in Anopheles gambiae complex populations from Burkina Faso, West Africa. Acta Trop. 2019;197:105054. doi: 10.1016/j.actatropica.2019.105054. PubMed PMID: 31175862.

 38. Epopa PS, Collins CM, North A, Millogo AA, Benedict MQ, Tripet F, Diabate A. Seasonal malaria vector and transmission dynamics in western Burkina Faso. Malar J. 2019;18(1):113.

doi: 10.1186/s12936-019-2747-5. PubMed PMID: 30940141; PMCID: PMC6444393.

908 39. Soma DD, Zogo BM, Some A, Tchiekoi BN, Hien DFS, Pooda HS, Coulibaly S, 309 Gnambani JE, Ouari A, Mouline K, Dahounto A, Ouedraogo GA, Fournet F, Koffi AA, P

Gnambani JE, Ouari A, Mouline K, Dahounto A, Ouedraogo GA, Fournet F, Koffi AA, Pennetier

C, Moiroux N, Dabire RK. Anopheles bionomics, insecticide resistance and malaria transmission

911 in southwest Burkina Faso: A pre-intervention study. PLoS One. 2020;15(8):e0236920. doi:<br>912 10.1371/journal.pone.0236920. PubMed PMID: 32745085; PMCID: PMC7398507. 10.1371/journal.pone.0236920. PubMed PMID: 32745085; PMCID: PMC7398507.

40. Dabire KR, Baldet T, Diabate A, Dia I, Costantini C, Cohuet A, Guiguemde TR,

Fontenille D. Anopheles funestus (Diptera: Culicidae) in a humid savannah area of western

Burkina Faso: bionomics, insecticide resistance status, and role in malaria transmission. J Med

 Entomol. 2007;44(6):990-7. doi: 10.1603/0022-2585(2007)44[990:afdcia]2.0.co;2. PubMed PMID: 18047197.

 41. Soma DD, Poda SB, Hien AS, Namountougou M, Sangare I, Sawadogo JME, Fournet F, Ouedraogo GA, Diabate A, Moiroux N, Dabire RK. Malaria vectors diversity, insecticide resistance and transmission during the rainy season in peri-urban villages of south-western 921 Burkina Faso. Malar J. 2021;20(1):63. doi: 10.1186/s12936-020-03554-5. PubMed PMID:<br>922 33494779: PMCID: PMC7831184.

33494779; PMCID: PMC7831184.

 42. Taconet P, Porciani A, Soma DD, Mouline K, Simard F, Koffi AA, Pennetier C, Dabire RK, Mangeas M, Moiroux N. Data-driven and interpretable machine-learning modeling to explore the fine-scale environmental determinants of malaria vectors biting rates in rural Burkina Faso. Parasit Vectors. 2021;14(1):345. doi: 10.1186/s13071-021-04851-x. PubMed PMID: 34187546; PMCID: PMC8243492.

928 43. Epopa PS, Millogo AA, Collins CM, North AR, Benedict MQ, Tripet F, O'Loughlin S,<br>929 Dabire RK, Ouedraogo GA, Diabate A. Anopheles gambiae (s.l.) is found where few are loo Dabire RK, Ouedraogo GA, Diabate A. Anopheles gambiae (s.l.) is found where few are looking: assessing mosquito diversity and density outside inhabited areas using diverse sampling 931 methods. Parasit Vectors. 2020;13(1):516. doi: 10.1186/s13071-020-04403-9. PubMed PMID:<br>932 33059722; PMCID: PMC7558606. 33059722; PMCID: PMC7558606.

 44. Mawejje HD, Kilama M, Kigozi SP, Musiime AK, Kamya M, Lines J, Lindsey SW, Smith D, Dorsey G, Donnelly MJ, Staedke SG. Impact of seasonality and malaria control interventions on Anopheles density and species composition from three areas of Uganda with differing malaria endemicity. Malaria J. 2021;20(1). doi: doi: 10.1186/s12936-021-03675-5.

 45. O'Meara WP, Simmons R, Bullins P, Freedman B, Abel L, Mangeni J, Taylor SM, Obala AA. Mosquito Exposure and Malaria Morbidity: A Microlevel Analysis of Household Mosquito Populations and Malaria in a Population-Based Longitudinal Cohort in Western Kenya. J Infect Dis. 2020;221(7):1176-84. doi: 10.1093/infdis/jiz561. PubMed PMID: 31665350; PMCID:

PMC7325711.

 46. Morlais I, Nsango SE, Toussile W, Abate L, Annan Z, Tchioffo MT, Cohuet A, Awono-Ambene PH, Fontenille D, Rousset F, Berry A. Plasmodium falciparum mating patterns and

mosquito infectivity of natural isolates of gametocytes. PLoS One. 2015;10(4):e0123777. doi:

10.1371/journal.pone.0123777. PubMed PMID: 25875840; PMCID: PMC4397039.

47. Das S, Muleba M, Stevenson JC, Pringle JC, Norris DE. Beyond the entomological

inoculation rate: characterizing multiple blood feeding behavior and Plasmodium falciparum

multiplicity of infection in Anopheles mosquitoes in northern Zambia. Parasit Vectors.

 2017;10(1):45. doi: 10.1186/s13071-017-1993-z. PubMed PMID: 28122597; PMCID: PMC5267472. 48. Kanatani S, Stiffler D, Bousema T, Yenokyan G, Sinnis P. Revisiting the Plasmodium sporozoite inoculum and elucidating the efficiency with which malaria parasites progress through the mosquito. Nat Commun. 2024;15(1):748. doi: 10.1038/s41467-024-44962-4. PubMed PMID: 38272943; PMCID: PMC10811227. 49. Andolina C, Graumans W, Guelbeogo M, van Gemert GJ, Ramijth J, Harouna S, Soumanaba Z, Stoter R, Vegte-Bolmer M, Pangos M, Sinnis P, Collins K, Staedke SG, Tiono AB, Drakeley C, Lanke K, Bousema T. Quantification of sporozoite expelling by Anopheles 958 mosquitoes infected with laboratory and naturally circulating P. falciparum gametocytes. Elife.<br>959 2024;12. doi: 10.7554/eLife.90989. PubMed PMID: 38517746; PMCID: PMC10959522. 2024;12. doi: 10.7554/eLife.90989. PubMed PMID: 38517746; PMCID: PMC10959522. 50. Pampiglioni S, Majori G, Petrangeli G, Romi R. Avermectins, MK-933 and MK-936, for mosquito control. Trans R Soc Trop Med Hyg. 1985;79:797-9. 51. Crump A, Omura S. Ivermectin, 'wonder drug' from Japan: the human use perspective. Proceedings of the Japan Academy Series B, Physical and biological sciences. 2011;87(2):13- 28. Epub 2011/02/16. PubMed PMID: 21321478; PMCID: 3043740. 52. Bockarie MJ, Hii JL, Alexander ND, Bockarie F, Dagoro H, Kazura JW, Alpers MP. Mass treatment with ivermectin for filariasis control in Papua New Guinea: impact on mosquito survival. Med Vet Entomol. 1999;13(2):120-3. PubMed PMID: 10484157. 53. Chaccour C, Lines J, Whitty CJ. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010;202(1):113-6. PubMed PMID: 20482251. 971 54. Kobylinski KC, Sylla M, Chapman PL, Sarr MD, Foy BD. Ivermectin mass drug<br>972 administration to humans disrupts malaria parasite transmission in Senegalese villages administration to humans disrupts malaria parasite transmission in Senegalese villages. Am J Trop Med Hyg. 2011;85(1):3-5. Epub 2011/07/08. doi: 10.4269/ajtmh.2011.11-0160. PubMed PMID: 21734116; PMCID: 3122335. 55. Smit MR, Ochomo E, Aljayyoussi G, Kwambai T, Abong'o B, Bayoh N, Gimnig J, Samuels A, Desai M, Phillips-Howard PA, Kariuki S, Wang D, Ward S, Ter Kuile FO. Efficacy and Safety of High-Dose Ivermectin for Reducing Malaria Transmission (IVERMAL): Protocol for a Double-Blind, Randomized, Placebo-Controlled, Dose-Finding Trial in Western Kenya. JMIR Res Protoc. 2016;5(4):e213. doi: 10.2196/resprot.6617. PubMed PMID: 27856406; PMCID: PMC5133431. 56. The Ivermectin Roadmappers, Billingsley P, Binka F, Chaccour C, Foy B, Gold S, Gonzalez-Silva M, Jacobson J, Jagoe G, Jones C, Kachur P, Kobylinski K, Last A, Lavery JV, Mabey D, Mboera D, Mbogo C, Mendez-Lopez A, Rabinovich NR, Rees S, Richards F, Rist C, Rockwood J, Ruiz-Castillo P, Sattabongkot J, Saute F, Slater H, Steer A, Xia K, Zullinger R. A Roadmap for the Development of Ivermectin as a Complementary Malaria Vector Control Tool. Am J Trop Med Hyg. 2020;102(2s):3-24. doi: 10.4269/ajtmh.19-0620. PubMed PMID: 31971144; PMCID: PMC7008306. 988 57. Kositz C, Bradley J, Hutchins H, Last A, D'Alessandro U, Marks M. Broadening the 989 range of use cases for ivermectin - a review of the evidence. Trans R Soc Trop Med Hyg. range of use cases for ivermectin - a review of the evidence. Trans R Soc Trop Med Hyg. 2022;116(3):201-12. doi: 10.1093/trstmh/trab114. PubMed PMID: 34323283; PMCID: 991 PMC8890779.<br>992 58. Foy BD 58. Foy BD, Alout H, Seaman JA, Rao S, Magalhaes T, Wade M, Parikh S, Soma DD, Sagna AB, Fournet F, Slater HC, Bougma R, Drabo F, Diabate A, Coulidiaty AGV, Rouamba N, Dabire RK. Efficacy and risk of harms of repeat ivermectin mass drug administrations for control of malaria (RIMDAMAL): a cluster-randomised trial. Lancet. 2019. doi: 10.1016/S0140- 6736(18)32321-3. PubMed PMID: 30878222. 59. Foy BD, Some A, Magalhaes T, Gray L, Rao S, Sougue E, Jackson CL, Kittelson J, Slater HC, Bousema T, Da O, Coulidiaty AGV, Colt M, Wade M, Richards K, Some AF, Dabire RK, Parikh S. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a

 Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. JMIR Res Protoc. 2023;12:e41197. doi: 10.2196/41197. PubMed PMID: 36939832; PMCID: PMC10132043.

 60. Dabira ED, Soumare HM, Lindsay SW, Conteh B, Ceesay F, Bradley J, Kositz C, Broekhuizen H, Kandeh B, Fehr AE, Nieto-Sanchez C, Ribera JM, Peeters Grietens K, Smit MR, Drakeley C, Bousema T, Achan J, D'Alessandro U. Mass Drug Administration With High- Dose Ivermectin and Dihydroartemisinin-Piperaquine for Malaria Elimination in an Area of Low Transmission With High Coverage of Malaria Control Interventions: Protocol for the MASSIV Cluster Randomized Clinical Trial. JMIR Res Protoc. 2020;9(11):e20904. doi: 10.2196/20904. 1009 PubMed PMID: 33211022; PMCID: PMC7714640.<br>1010 61. Hutchins H. Bradley J. Pretorius E. Teixeira

61. Hutchins H, Bradley J, Pretorius E, Teixeira da Silva E, Vasileva H. Jones RT. Ndiath MO, Dit Massire Soumare H, Mabey D, Nante EJ, Martins C, Logan JG, Slater H, Drakeley C, D'Alessandro U, Rodrigues A, Last AR. Protocol for a cluster randomised placebo-controlled trial of adjunctive ivermectin mass drug administration for malaria control on the Bijagos

Archipelago of Guinea-Bissau: the MATAMAL trial. BMJ Open. 2023;13(7):e072347. doi:

- 10.1136/bmjopen-2023-072347. PubMed PMID: 37419638; PMCID: PMC10335573.
- 62. Chaccour C, Casellas A, Hammann F, Ruiz-Castillo P, Nicolas P, Montana J, Mael M, Selvaraj P, Duthaler U, Mrema S, Kakolwa M, Lyimo I, Okumu F, Marathe A, Schurch R,
- Elobolobo E, Sacoor C, Saute F, Xia K, Jones C, Rist C, Maia M, Rabinovich NR. BOHEMIA:
- 1019 Broad One Health Endectocide-based Malaria Intervention in Africa-a phase III cluster-<br>1020 Frandomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass randomized, open-label, clinical trial to study the safety and efficacy of ivermectin mass drug
- administration to reduce malaria transmission in two African settings. Trials. 2023;24(1):128.
- doi: 10.1186/s13063-023-07098-2. PubMed PMID: 36810194; PMCID: PMC9942013.
- 63. World Health Organization. World Malaria Report 2023.
- 64. Taylor SM, Messina JP, Hand CC, Juliano JJ, Muwonga J, Tshefu AK, Atua B, Emch M, Meshnick SR. Molecular malaria epidemiology: mapping and burden estimates for the Democratic Republic of the Congo, 2007. PLoS One. 2011;6(1):e16420. doi:
- 10.1371/journal.pone.0016420. PubMed PMID: 21305011; PMCID: PMC3031549.
- 65. Woldearegai TG, Lalremruata A, Nguyen TT, Gmeiner M, Veletzky L, Tazemda-Kuitsouc GB, Matsiegui PB, Mordmuller B, Held J. Characterization of Plasmodium infections among inhabitants of rural areas in Gabon. Sci Rep. 2019;9(1):9784. doi: 10.1038/s41598-019-46194- 9. PubMed PMID: 31278305; PMCID: PMC6611864.
- 66. Abdulraheem MA, Ernest M, Ugwuanyi I, Abkallo HM, Nishikawa S, Adeleke M, Orimadegun AE, Culleton R. High prevalence of Plasmodium malariae and Plasmodium ovale in co-infections with Plasmodium falciparum in asymptomatic malaria parasite carriers in southwestern Nigeria. Int J Parasitol. 2022;52(1):23-33. doi: 10.1016/j.ijpara.2021.06.003. PubMed PMID: 34390743.
- 67. Amoah LE, Asare KK, Dickson D, Anang SF, Busayo A, Bredu D, Asumah G, Peprah N, Asamoah A, Abuaku B, Malm KL. Nationwide molecular surveillance of three Plasmodium 1039 species harboured by symptomatic malaria patients living in Ghana. Parasit Vectors.<br>1040 2022;15(1):40. doi: 10.1186/s13071-022-05153-6. PubMed PMID: 35090545; PMCID 2022;15(1):40. doi: 10.1186/s13071-022-05153-6. PubMed PMID: 35090545; PMCID:
- PMC8796507.
- 68. Amoah LE, Donu D, Abuaku B, Ahorlu C, Arhinful D, Afari E, Malm K, Koram KA. Probing the composition of Plasmodium species contained in malaria infections in the Eastern region of Ghana. BMC Public Health. 2019;19(1):1617. doi: 10.1186/s12889-019-7989-1. PubMed PMID: 31791319; PMCID: PMC6889690.
- 1046 69. Nguiffo-Nguete D, Nongley Nkemngo F, Ndo C, Agbor JP, Boussougou-Sambe ST,<br>1047 Salako Djogbenou L, Ntoumi F, Adegnika AA, Borrmann S, Wondii CS. Plasmodium malari Salako Djogbenou L, Ntoumi F, Adegnika AA, Borrmann S, Wondji CS. Plasmodium malariae contributes to high levels of malaria transmission in a forest-savannah transition area in
- 
- Cameroon. Parasit Vectors. 2023;16(1):31. doi: 10.1186/s13071-022-05635-7. PubMed PMID:
- 36698132; PMCID: PMC9875470.

 70. Oriero EC, Olukosi AY, Oduwole OA, Djimde A, D'Alessandro U, Meremikwu MM, Amambua-Ngwa A. Seroprevalence and Parasite Rates of Plasmodium malariae in a High Malaria Transmission Setting of Southern Nigeria. Am J Trop Med Hyg. 2020;103(6):2208-16. doi: 10.4269/ajtmh.20-0593. PubMed PMID: 33124531; PMCID: PMC7695047.

 71. Quaye IK, Aleksenko L, Oeuvray C, Yewhalaw D, Duah N, Gyan B, Haiyambo DH, Dongho GBD, Torgby RA, Amoah L, Hamid MA, Worku S, Bahiti AA, Pasquale HA, Bitshi M, Troare I, Diarra A, Njunju E, Cisse M, Soulama I, Savadogo RJ, Issifou S, Niangaly A, Dembele L, Greco B. The Pan African Vivax and Ovale Network (PAVON): Refocusing on Plasmodium vivax, ovale and asymptomatic malaria in sub-Saharan Africa. Parasitol Int. 2021;84:102415. doi: 10.1016/j.parint.2021.102415. PubMed PMID: 34216801.

- 72. Sendor R, Mitchell CL, Chacky F, Mohamed A, Mhamilawa LE, Molteni F, Nyinondi S, Kabula B, Mkali H, Reaves EJ, Serbantez N, Kitojo C, Makene T, Kyaw T, Muller M, Mwanza A, Eckert EL, Parr JB, Lin JT, Juliano JJ, Ngasala B. Similar Prevalence of Plasmodium falciparum and Non-P. falciparum Malaria Infections among Schoolchildren, Tanzania(1). Emerg Infect Dis. 2023;29(6):1143-53. doi: 10.3201/eid2906.221016. PubMed PMID: 37209670; PMCID: PMC10202886.
- 73. Hawadak J, Dongang Nana RR, Singh V. Global trend of Plasmodium malariae and Plasmodium ovale spp. malaria infections in the last two decades (2000-2020): a systematic review and meta-analysis. Parasit Vectors. 2021;14(1):297. doi: 10.1186/s13071-021-04797-0. PubMed PMID: 34082791; PMCID: PMC8173816.
- 74. Sagna AB, Zela L, Ouedraogo COW, Pooda SH, Porciani A, Furnival-Adams J, Lado P, Some AF, Pennetier C, Chaccour CJ, Dabire RK, Mouline K. Ivermectin as a novel malaria control tool: Getting ahead of the resistance curse. Acta Trop. 2023;245:106973. doi:
- 10.1016/j.actatropica.2023.106973. PubMed PMID: 37352998.
- 75. Taconet P, Zogo B, Soma DD, Ahoua Alou LP, Mouline K, Dabire RK, Amanan Koffi A, Pennetier C, Moiroux N. Anopheles sampling collections in the health districts of Korhogo (Cote d'Ivoire) and Diebougou (Burkina Faso) between 2016 and 2018. GigaByte.
- 2023;2023:gigabyte83. doi: 10.46471/gigabyte.83. PubMed PMID: 37408730; PMCID:
- 1079 PMC10318348.<br>1080 76. McMaho 76. McMahon A, Franca CMB, Wimberly MC. Comparing Satellite and Ground-Based
- Measurements of Environmental Suitability for Vector Mosquitoes in an Urban Landscape. J Med Entomol. 2022;59(6):1936-46. doi: 10.1093/jme/tjac145. PubMed PMID: 36189969;
- PMCID: PMC9667728.
- 77. Snounou G, Pinheiro L, Goncalves A, Fonseca L, Dias F, Brown KN, do Rosario VE.
- The importance of sensitive detection of malaria parasites in the human and insect hosts in
- epidemiological studies, as shown by the analysis of field samples from Guinea Bissau. Trans R Soc Trop Med Hyg. 1993;87(6):649-53. doi: 10.1016/0035-9203(93)90274-t. PubMed PMID: 8296364.
- 78. Nsobya SL, Parikh S, Kironde F, Lubega G, Kamya MR, Rosenthal PJ, Dorsey G. 1090 Molecular evaluation of the natural history of asymptomatic parasitemia in Ugandan children. J<br>1091 Infect Dis. 2004:189(12):2220-6. doi: 10.1086/421281. PubMed PMID: 15181569. Infect Dis. 2004;189(12):2220-6. doi: 10.1086/421281. PubMed PMID: 15181569.
- 79. Murphy SC, Shott JP, Parikh S, Etter P, Prescott WR, Stewart VA. Malaria diagnostics in
- clinical trials. Am J Trop Med Hyg. 2013;89(5):824-39. doi: 10.4269/ajtmh.12-0675. PubMed PMID: 24062484; PMCID: PMC3820323.
- 80. Beadle C, Long GW, Weiss WR, McElroy PD, Maret SM, Oloo AJ, Hoffman SL.
- Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet. 1994;343(8897):564-8. doi: 10.1016/s0140-6736(94)91520-2. PubMed PMID: 7906328.
- 81. Poti KE, Sullivan DJ, Dondorp AM, Woodrow CJ. HRP2: Transforming Malaria
- Diagnosis, but with Caveats. Trends Parasitol. 2020;36(2):112-26. doi:
- 10.1016/j.pt.2019.12.004. PubMed PMID: 31848119.

 82. WHO. World Malaria Report 2023. Geneva: World Health Organization, 2023. 83. Singh B. Molecular methods for diagnosis and epidemiological studies of parasitic infections. Int J Parasitol. 1997;27(10):1135-45. doi: 10.1016/s0020-7519(97)00111-2. PubMed PMID: 9394184. 84. Abba K, Deeks JJ, Olliaro P, Naing CM, Jackson SM, Takwoingi Y, Donegan S, Garner P. Rapid diagnostic tests for diagnosing uncomplicated P. falciparum malaria in endemic countries. The Cochrane database of systematic reviews. 2011;2011(7):CD008122. doi: 10.1002/14651858.CD008122.pub2. PubMed PMID: 21735422; PMCID: PMC6532563. 85. Maltha J, Gillet P, Jacobs J. Malaria rapid diagnostic tests in endemic settings. Clin Microbiol Infect. 2013;19(5):399-407. doi: 10.1111/1469-0691.12151. PubMed PMID: 23438048. 86. Jimenez A, Rees-Channer RR, Perera R, Gamboa D, Chiodini PL, Gonzalez IJ, Mayor A, Ding XC. Analytical sensitivity of current best-in-class malaria rapid diagnostic tests. Malar J. 2017;16(1):128. doi: 10.1186/s12936-017-1780-5. PubMed PMID: 28340585; PMCID: PMC5366122. 87. Farcas GA, Zhong KJ, Lovegrove FE, Graham CM, Kain KC. Evaluation of the Binax NOW ICT test versus polymerase chain reaction and microscopy for the detection of malaria in returned travelers. Am J Trop Med Hyg. 2003;69(6):589-92. PubMed PMID: 14740873. 88. Ratsimbasoa A, Randriamanantena A, Raherinjafy R, Rasoarilalao N, Menard D. Which malaria rapid test for Madagascar? Field and laboratory evaluation of three tests and expert microscopy of samples from suspected malaria patients in Madagascar. Am J Trop Med Hyg. 2007;76(3):481-5. PubMed PMID: 17360871. 89. Khairnar K, Martin D, Lau R, Ralevski F, Pillai DR. Multiplex real-time quantitative PCR, microscopy and rapid diagnostic immuno-chromatographic tests for the detection of Plasmodium spp: performance, limit of detection analysis and quality assurance. Malar J. 2009;8:284. doi: 10.1186/1475-2875-8-284. PubMed PMID: 20003199; PMCID: PMC2796674. 90. Sokhna C, Cisse B, Ba el H, Milligan P, Hallett R, Sutherland C, Gaye O, Boulanger D, Simondon K, Simondon F, Targett G, Lines J, Greenwood B, Trape JF. A trial of the efficacy, 1130 safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive<br>1131 treatment for malaria in Senegalese children. PLoS One. 2008;3(1):e1471. doi: treatment for malaria in Senegalese children. PLoS One. 2008;3(1):e1471. doi: 10.1371/journal.pone.0001471. PubMed PMID: 18213379; PMCID: PMC2198946. 91. Dicko A, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, Santara G, Diawara H, Conare T, Djimde A, Chandramohan D, Cousens S, Milligan PJ, Diallo DA, Doumbo OK, Greenwood B. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Mali: a randomised, double-blind, placebo-controlled trial. PLoS Med. 2011;8(2):e1000407. doi: 10.1371/journal.pmed.1000407. PubMed PMID: 21304923; PMCID: PMC3032550. 92. Tagbor H, Antwi GD, Acheampong PR, Bart Plange C, Chandramohan D, Cairns M. 1140 Seasonal malaria chemoprevention in an area of extended seasonal transmission in Ashanti,<br>1141 Ghana: an individually randomised clinical trial. Trop Med Int Health. 2016;21(2):224-35. doi: Ghana: an individually randomised clinical trial. Trop Med Int Health. 2016;21(2):224-35. doi: 10.1111/tmi.12642. PubMed PMID: 26578353; PMCID: PMC4982104. 93. Cisse B, Ba EH, Sokhna C, JL ND, Gomis JF, Dial Y, Pitt C, M ND, Cairns M, Faye E, M ND, Lo A, Tine R, Faye S, Faye B, Sy O, Konate L, Kouevijdin E, Flach C, Faye O, Trape JF, Sutherland C, Fall FB, Thior PM, Faye OK, Greenwood B, Gaye O, Milligan P. Effectiveness of Seasonal Malaria Chemoprevention in Children under Ten Years of Age in Senegal: A Stepped- Wedge Cluster-Randomised Trial. PLoS Med. 2016;13(11):e1002175. doi: 10.1371/journal.pmed.1002175. PubMed PMID: 27875528; PMCID: PMC5119693. 94. Diawara SI, Konate D, Kayentao K, Mihigo J, Shaffer JG, Sangare M, Ndabamenye P, Swedberg E, Garg LW, Gamache N, Keita B, Kamate B, Ndaruhutse P, Kone D, Sanogo V, Tounkara M, Diakite M, Doumbia S, Eckert E. Effect of seasonal malaria chemoprevention in children between 5 and 9 years old in Kita and Bafoulabe districts, Mali. Parasite Epidemiol

 Control. 2022;18:e00258. doi: 10.1016/j.parepi.2022.e00258. PubMed PMID: 35789762; PMCID: PMC9249800. 95. Ansah PO, Ansah NA, Malm K, Awuni D, Peprah N, Dassah S, Yarig S, Manful C, Agbenyeri J, Awoonor-Williams J, Ofosu W, Oduro AR. Evaluation of pilot implementation of seasonal malaria chemoprevention on morbidity in young children in Northern Sahelian Ghana. Malar J. 2021;20(1):440. doi: 10.1186/s12936-021-03974-x. PubMed PMID: 34794431; PMCID: PMC8600740. 96. Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, Nikiema F, Tapily A, Sompougdou F, Issiaka D, Zoungrana C, Sanogo K, Haro A, Kaya M, Sienou AA, 1162 Traore S, Mahamar A, Thera I, Diarra K, Dolo A, Kuepfer I, Snell P, Milligan P, Ockenhouse C, 1163 (Ofori-Anyinam O, Tinto H, Dijmde A, Ouedraogo JB, Dicko A, Greenwood B. Seasonal Malaria Ofori-Anyinam O, Tinto H, Djimde A, Ouedraogo JB, Dicko A, Greenwood B. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. N Engl J Med. 2021;385(11):1005-17. doi: 10.1056/NEJMoa2026330. PubMed PMID: 34432975. 97. Coldiron ME, Assao B, Guindo O, Sayinzoga-Makombe N, Koscalova A, Sterk E, Quere M, Ciglenecki I, Mumina A, Atti S, Langendorf C, Grais RF. Prevalence of malaria in an area receiving seasonal malaria chemoprevention in Niger. Malar J. 2021;20(1):419. doi: 10.1186/s12936-021-03953-2. PubMed PMID: 34689782; PMCID: PMC8543849. 98. Faye FB, Spiegel A, Tall A, Sokhna C, Fontenille D, Rogier C, Trape JF. Diagnostic criteria and risk factors for Plasmodium ovale malaria. J Infect Dis. 2002;186(5):690-5. doi: 10.1086/342395. PubMed PMID: 12195357. 99. Collins WE, Jeffery GM. Plasmodium malariae: parasite and disease. Clin Microbiol Rev. 2007;20(4):579-92. doi: 10.1128/CMR.00027-07. PubMed PMID: 17934075; PMCID: PMC2176047. 100. Collins WE, Jeffery GM. Plasmodium ovale: parasite and disease. Clin Microbiol Rev. 2005;18(3):570-81. doi: 10.1128/CMR.18.3.570-581.2005. PubMed PMID: 16020691; PMCID: PMC1195966. 101. Nambunga IH, Ngowo HS, Mapua SA, Hape EE, Msugupakulya BJ, Msaky DS, Mhumbira NT, McHwembo KR, Tamayamali GZ, Mlembe SV, Njalambaha RM, Lwetoijera DW, Finda MF, Govella NJ, Matoke-Muhia D, Kaindoa EW, Okumu FO. Aquatic habitats of the malaria vector Anopheles funestus in rural south-eastern Tanzania. Malar J. 2020;19(1):219. doi: 10.1186/s12936-020-03295-5. PubMed PMID: 32576200; PMCID: PMC7310514. 102. Scott TW, Takken W. Feeding strategies of anthropophilic mosquitoes result in increased risk of pathogen transmission. Trends Parasitol. 2012;28(3):114-21. doi: 10.1016/j.pt.2012.01.001. PubMed PMID: 22300806. 103. Bartholomay LC, Michel K. Mosquito Immunobiology: The Intersection of Vector Health and Vector Competence. Annu Rev Entomol. 2018;63:145-67. doi: 10.1146/annurev-ento- 010715-023530. PubMed PMID: 29324042. 104. McKenzie FE, Bossert WH. Mixed-species Plasmodium infections of Anopheles (Diptera:Culicidae). J Med Entomol. 1997;34(4):417-25. doi: 10.1093/jmedent/34.4.417. PubMed PMID: 9220675; PMCID: PMC2500223. 105. Shaw WR, Marcenac P, Catteruccia F. Plasmodium development in Anopheles: a tale of shared resources. Trends Parasitol. 2022;38(2):124-35. doi: 10.1016/j.pt.2021.08.009. PubMed 1195 PMID: 34548252; PMCID: PMC8758519.<br>1196 106. Arez AP, Pinto J, Palsson K, Snou 106. Arez AP, Pinto J, Palsson K, Snounou G, Jaenson TG, do Rosario VE. Transmission of mixed Plasmodium species and Plasmodium falciparum genotypes. Am J Trop Med Hyg. 2003;68(2):161-8. PubMed PMID: 12641406. 1199 107. Imwong M, Nakeesathit S, Day NP, White NJ. A review of mixed malaria species<br>1200 infections in anopheline mosquitoes. Malar J. 2011:10:253. doi: 10.1186/1475-2875-10-2 infections in anopheline mosquitoes. Malar J. 2011;10:253. doi: 10.1186/1475-2875-10-253. PubMed PMID: 21880138; PMCID: PMC3201030. 108. Balasubramanian S, Rahman RS, Lon C, Parobek C, Ubalee R, Hathaway N, Kuntawunginn W, My M, Vy D, Saxe J, Lanteri C, Lin FC, Spring M, Meshnick SR, Juliano JJ,

- Saunders DL, Lin JT. Efficient Transmission of Mixed Plasmodium falciparum/vivax Infections
- From Humans to Mosquitoes. J Infect Dis. 2020;221(3):428-37. doi: 10.1093/infdis/jiz388.
- PubMed PMID: 31549156; PMCID: PMC7184918.
- 109. Robinson A, Busula AO, Voets MA, Beshir KB, Caulfield JC, Powers SJ, Verhulst NO,
- Winskill P, Muwanguzi J, Birkett MA, Smallegange RC, Masiga DK, Mukabana WR, Sauerwein
- RW, Sutherland CJ, Bousema T, Pickett JA, Takken W, Logan JG, de Boer JG. Plasmodium-
- associated changes in human odor attract mosquitoes. Proc Natl Acad Sci U S A.
- 2018;115(18):E4209-E18. doi: 10.1073/pnas.1721610115. PubMed PMID: 29666273; PMCID: PMC5939094.
- 1213 110. MR4. Methods in Anopheles Research 2014. Available from:<br>1214 https://www.beiresources.org/portals/2/MR4/MR4 Publications/Meth
- [https://www.beiresources.org/portals/2/MR4/MR4\\_Publications/Methods%20in%20Anopheles%](https://www.beiresources.org/portals/2/MR4/MR4_Publications/Methods%20in%20Anopheles%20Research%202014/2014MethodsinAnophelesResearchManualFullVersionv2tso.pdf) [20Research%202014/2014MethodsinAnophelesResearchManualFullVersionv2tso.pdf.](https://www.beiresources.org/portals/2/MR4/MR4_Publications/Methods%20in%20Anopheles%20Research%202014/2014MethodsinAnophelesResearchManualFullVersionv2tso.pdf)
- 
- 1216 111. Burkot TR, Zavala F, Gwadz RW, Collins FH, Nussenzweig RS, Roberts DR.<br>1217 Identification of malaria-infected mosquitoes by a two-site enzyme-linked immunosor Identification of malaria-infected mosquitoes by a two-site enzyme-linked immunosorbent assay. Am J Trop Med Hyg. 1984;33(2):227-31. doi: 10.4269/ajtmh.1984.33.227. PubMed PMID:
- 6370003.
- 1220 112. Beier JC, Perkins PV, Koros JK, Onyango FK, Gargan TP, Wirtz RA, Koech DK, Roberts<br>1221 CR. Malaria sporozoite detection by dissection and ELISA to assess infectivity of afrotropical
- CR. Malaria sporozoite detection by dissection and ELISA to assess infectivity of afrotropical
- Anopheles (Diptera: Culicidae). J Med Entomol. 1990;27(3):377-84. doi:
- 10.1093/jmedent/27.3.377. PubMed PMID: 2185363.
- 113. Durnez L, Van Bortel W, Denis L, Roelants P, Veracx A, Trung HD, Sochantha T,
- Coosemans M. False positive circumsporozoite protein ELISA: a challenge for the estimation of 1226 the entomological inoculation rate of malaria and for vector incrimination. Malar J. 2011;10:195.<br>1227 doi: 10.1186/1475-2875-10-195. PubMed PMID: 21767376: PMCID: PMC3160429.
- doi: 10.1186/1475-2875-10-195. PubMed PMID: 21767376; PMCID: PMC3160429.
- 114. Echeverry DF, Deason NA, Makuru V, Davidson J, Xiao H, Niedbalski J, Yu X,
- Stevenson JC, Bugoro H, Aparaimo A, Reuben H, Cooper R, Burkot TR, Russell TL, Collins FH,
- Lobo NF. Fast and robust single PCR for Plasmodium sporozoite detection in mosquitoes using
- the cytochrome oxidase I gene. Malar J. 2017;16(1):230. doi: 10.1186/s12936-017-1881-1. 1232 PubMed PMID: 28569159; PMCID: PMC5452387.<br>1233 115. Ogola EO, Fillinger U, Ondiba IM, Villinger.
- 115. Ogola EO, Fillinger U, Ondiba IM, Villinger J, Masiga DK, Torto B, Tchouassi DP.
- Insights into malaria transmission among Anopheles funestus mosquitoes, Kenya. Parasit
- Vectors. 2018;11(1):577. doi: 10.1186/s13071-018-3171-3. PubMed PMID: 30400976; PMCID: 1236 PMC6219006.<br>1237 116. Foley D
- 116. Foley DH, Harrison G, Murphy JR, Dowler M, Rueda LM, Wilkerson RC. Mosquito
- bisection as a variable in estimates of PCR-derived malaria sporozoite rates. Malar J.
- 2012;11:145. doi: 10.1186/1475-2875-11-145. PubMed PMID: 22551078; PMCID:
- PMC3411414.
- 117. Diagne N, Fontenille D, Konate L, Faye O, Lamizana MT, Legros F, Molez JF, Trape JF. [Anopheles of Senegal. An annotated and illustrated list]. Bull Soc Pathol Exot. 1994;87(4):267-
- 77. PubMed PMID: 7866049. 118. Gillies MT, Coetzee M. A supplement to the Anophelinae of Africa South of the Sahara (Afrotropical Region). S Afr Inst Med Res. 1987:143.
- 119. Wilkins EE, Howell PI, Benedict MQ. IMP PCR primers detect single nucleotide
- polymorphisms for Anopheles gambiae species identification, Mopti and Savanna rDNA types,
- and resistance to dieldrin in Anopheles arabiensis. Malar J. 2006;5:125. doi: 10.1186/1475- 2875-5-125. PubMed PMID: 17177993; PMCID: PMC1769388.
- 1250 120. Koekemoer LL, Kamau L, Hunt RH, Coetzee M. A cocktail polymerase chain reaction<br>1251 assay to identify members of the Anopheles funestus (Diptera: Culicidae) group. Am J Trop M assay to identify members of the Anopheles funestus (Diptera: Culicidae) group. Am J Trop Med Hyg. 2002;66(6):804-11. doi: 10.4269/ajtmh.2002.66.804. PubMed PMID: 12224596.
- 121. Maddison WP, Maddison DR. Mesquite: a modular system for evolutionary analysis. 2021.

- 122. Hofmann N, Mwingira F, Shekalaghe S, Robinson LJ, Mueller I, Felger I. Ultra-sensitive detection of Plasmodium falciparum by amplification of multi-copy subtelomeric targets. PLoS Med. 2015;12(3):e1001788. doi: 10.1371/journal.pmed.1001788. PubMed PMID: 25734259; PMCID: PMC4348198.
- 123. Phuong M, Lau R, Ralevski F, Boggild AK. Sequence-based optimization of a
- quantitative real-time PCR assay for detection of Plasmodium ovale and Plasmodium malariae.
- J Clin Microbiol. 2014;52(4):1068-73. doi: 10.1128/JCM.03477-13. PubMed PMID: 24430459;
- PMCID: PMC3993485.
- 124. Kent RJ, Norris DE. Identification of mammalian blood meals in mosquitoes by a
- 1264 multiplexed polymerase chain reaction targeting cytochrome B. Am J Trop Med Hyg.<br>1265 0005:73(2):336-42. PubMed PMID: 16103600: PMCID: PMC4147110.
- 2005;73(2):336-42. PubMed PMID: 16103600; PMCID: PMC4147110.
-